Skip to content

Expressive Writing for COVID-19 Resilience

Expressive Writing for COVID-19 Resilience

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04589104
Enrollment
63
Registered
2020-10-19
Start date
2020-05-26
Completion date
2020-08-17
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distress Due to COVID-19

Brief summary

The purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the COVID-19 pandemic during spring 2020.

Detailed description

The purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the COVID-19 pandemic during spring 2020. Eligible subjects will be adults who are able to read and write in English and are cognitively able to provide informed consent. Potential subjects will be recruited through the Duke Health & Well-Being email lists. The entirely virtual 6-week expressive writing intervention will be delivered via Zoom, REDCap, and email, and subjects will complete measures at baseline, 6 weeks, and 10 weeks (1 month post-intervention). Each week of the intervention will invite participants to complete a series of expressive writing assignments designed to support emotional expression and cultivate resilience, and the assignments will take approximately 60-90 minutes each week to complete. The primary outcome is the 25-item Connor-Davidson Resilience Scale (CD-RISC). Other measures will include a basic demographics survey, questions about COVID-19 impact, post-writing surveys collected after the writing assignments, the 10-item Perceived Stress Scale (PSS), the Center for Epidemiologic Studies Depression Scale-Revised, and the 21-item Post -Traumatic Growth Inventory (PTGI). Participants will also have the option to share the content of their writing assignments with the research team if they choose. The risks of participation in this study are minimal and include the risk of mild sadness after the writing assignments and the risk of loss of confidentiality.

Interventions

BEHAVIORALExpressive writing

The expressive writing intervention consists of a 6-week, virtually-delivered writing program. Each week, participants meet for 90 minutes via Zoom and will be guided through writing prompts designed to encourage emotional expression and enhance personal resilience. The progression of writing exercises flows as follows: * Week 1: Writing to expressive difficult emotions * Week 2: Writing to release & integrate difficult emotions * Week 3: Writing to nurture gratitude * Week 4: Writing to enhance strengths & resources * Week 5: Writing to cultivate positive meaning & savor goodness * Week 6: Writing to invite insight, perspective, & growth

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Potential subjects will be considered eligible if they feel they have been personally impacted by circumstances surrounding COVID-19. Other eligibility criteria include: * Able to speak, read, write, and understand English * Cognitively able to provide consent * Ability to participate in a 6-week intervention delivered via Zoom, REDCap, and email

Design outcomes

Primary

MeasureTime frameDescription
Resilience3 monthsConnor-Davidson Resilience Scale (CD-RISC)

Secondary

MeasureTime frameDescription
Perceived stress3 monthsPerceived Stress Scale-10 (PSS10)
Depression symptoms3 monthsCenter for Epidemiologic Studies Scale - Revised (CESDR)
Post-traumatic growth3 monthsPost Traumatic Growth Inventory (PTGI)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026